Jacobs Levy Equity Management, Inc Aldeyra Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 476,949 shares of ALDX stock, worth $2.28 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
476,949
Previous 181,085
163.38%
Holding current value
$2.28 Million
Previous $599,000
329.05%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$44.4 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$26.2 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$18 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.3 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$9.01 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $279M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...